雖然這篇dupixent賽諾菲鄉民發文沒有被收入到精華區:在dupixent賽諾菲這個話題中,我們另外找到其它相關的精選爆讚文章
[爆卦]dupixent賽諾菲是什麼?優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#1賽諾菲/再生元異位性皮膚炎藥達3期臨床主要終點有望成為首個 ...
美國時間30日,賽諾菲(Sanofi)和再生元(Regeneron)宣布,共同研發的明星藥物dupixent在治療6個月至5歲中度至重度異位性皮膚炎(atopic dermatitis,AD)患者 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#2再生元暢銷藥!輝瑞異位性皮膚炎口服藥3 期臨床解析 - 基因線上
勝過賽諾菲、再生元暢銷藥!輝瑞異位性皮膚炎口服藥3 期臨床解析 ; 異位性皮膚炎的市場潛力 ; Abrocitinib 與Dupixent 正面對決 ; 輝瑞:Abrocitinib 各指標 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#3《FDA》賽諾菲/Regeneron超級暢銷藥Dupixent新適應症獲 ...
就在賽諾菲(Sanofi)宣揚公司主力產品Dupixent的暢銷戰績後沒幾天,公司為Dupixent再添一好消息:賽諾菲與夥伴Regeneron宣佈,Dupixent擴充青少年輕 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#4賽諾菲藥廠調高全年財測因濕疹新藥印鈔力強 - 中華民國製藥 ...
法國製藥大廠賽諾菲(Sanofi)調升2017年全年獲利預估,理由是消費者保健品、疫苗與旗下健臻生技(Genzyme)事業第2季獲利強勁成長,而且濕疹新藥Dupixent獲得美國醫師 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#5DUPI - 藥品資料
廠商名稱:, 賽諾菲股份有限公司 ... 藥品英文名稱:, (審)(大)Dupixent 300mg/vial 2vial/box (需冷藏). 院內代碼:, DUPI. 主成份及含量:, Dupilumab 300mg/vial.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#62年翻3倍!赛诺菲摇钱树Dupixent一个季度销售额超10亿欧元!
在2019年加入赛诺菲后不久,其首席执行官Paul Hudson就抛出了一个雄心壮志,即尽可能多地投资,将与再生元合作的抗体药物Dupixent打造成一款超级重磅 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#7儿童特应性皮炎(AD)新药!赛诺菲/再生元Dupixent(达必妥)3期 ...
2021年08月30日讯/生物谷BIOON/ --赛诺菲(Sanofi)与再生元(Regeneron)近日联合宣布,评估靶向生物制剂Dupixent(中文商品名:达必妥,通用 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#8Dupixent® (dupilumab) pivotal trial meets all primary ... - Sanofi
Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes, including ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#9合一治療異位性皮膚炎新藥美國二期試驗明年上半年解盲 - 鉅亨
據法國藥廠賽諾菲報告指出,第一個被核准的異位性皮膚炎生物新藥,就是賽諾菲所開發上市的新藥Dupixent,美國年銷售額上看60 億歐元,未來將成長至100 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#10杜避炎注射劑(賽諾菲)
商品名, 中文藥名, 學名. Dupixent 300mg/2mL/Syringe, 杜避炎注射劑(賽諾菲), Dupilumab. 藥品碼, 2DUPIX. 劑型, 針劑. 顏色. 形狀. 印字. 刻痕. 藥品圖示.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#11DUPIXENT® (dupilumab) HCP Website
Questions or comments? ... to contact Regeneron Pharmaceuticals, Inc. © 2020 2021 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. DUPIXENT® and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#12合一治療異位性皮膚炎新藥美國二期試驗明年上半年解盲
據法國藥廠賽諾菲報告指出,第一個被核准的異位性皮膚炎生物新藥,就是賽諾菲所開發上市的新藥Dupixent,美國年銷售額上看60 億歐元,未來將成長至100 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#13項次 健保代碼 藥品名稱 成分及含量 規格量 藥商名稱 原支付價 ...
Dupixent solution for injection 300mg. dupilumab 300mg/2ml. 賽諾菲股份有限公司. --. 19,738. 1.本案藥品為新成分新藥。 2.依全民健康保險藥物給付項目及支付標準 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#14Take Action With DUPIXENT® (dupilumab)
to contact DUPIXENT MyWay®. © 2021 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. DUPIXENT® and DUPIXENT MyWay® are registered trademarks ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#15KC01082212 | 西藥資訊| 就醫指南 - 耕莘醫院
Dupixent Inj.-300mg/2ml/Syringe ... 賽諾菲. 製造廠國名 ... Dupilumab是一種IgG4人類單株抗體,它能專一性地結合於介白素-4 (IL-4)及介白素-13 (IL-13)受體複合體上 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#16<學術演講>賽諾菲股份有限公司 - 臺灣皮膚科醫學會
一、主辦單位:賽諾菲股份有限公司二、時間:108年3月17日(星期日) 三、 ... 05 四、主題:Leadership in Transformation-Dupixent Symposium 五、本會認定積分:3點 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#17赛诺菲/再生元Dupixent获FDA批准-资讯
分析测试,百科网,赛诺菲/再生元Dupixent获FDA批准, 法国制药巨头赛诺菲(Sanofi)与合作伙伴再生元(Regeneron)近日宣布,美国FDA已批准Dupixent(dupilumab)注射液 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#18達必妥- 維基百科,自由的百科全書
達必妥(英語:Dupixent)是一種單株抗體藥物,可用於治療過敏性疾病( ... Articles with erroneous molar mass calculations · 賽諾菲 · 突破療法 · 單株抗體類.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#19合一治療異位性皮膚炎新藥美國二期試驗明年上半年解盲
據法國藥廠賽諾菲報告指出,第一個被核准的異位性皮膚炎生物新藥,就是賽諾菲所開發上市的新藥Dupixent,美國年銷售額上看60 億歐元,未來將成長至100 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#20賽諾菲預計賣100億歐元Dupixent,未來計劃斬獲5個適應症
2017年3月底,賽諾菲與再生元合作開發的Dupixent獲FDA批准,成為全球首個治療中重度特應性皮炎的生物製劑。經歷短短三年的時間,Dupixent的年銷售額就 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#21Sanofi's €10B sales target for Dupixent? The 'megabrand' is ...
Once again, Sanofi's Dupixent and flu vaccines drove growth, but the company also had contributions from its oncology and rare disease ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#22Regeneron and Sanofi Announce Positive Results from Phase ...
In addition, the companies also announced that four earlier clinical studies of dupilumab in moderate-to-severe atopic dermatitis were published today in the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#23BioNews | 赛诺菲&再生元:Dupixent® (dupilumab) SmPC - 雪球
作者:林出. 微信公众号:蹊之美股生物医药/ CaesarBiotech. 标的公司:Regeneron Pharmaceuticals,Inc.(REGN)& Sanofi (SNY). 再生元(REGN)和赛诺菲 (SNY)宣布, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#24Sanofi、Regeneron最新的濕疹藥物Dupixent研究結果正面 ...
產業訊息. 若有任何問題,歡迎提供意見反應,我們會儘速處理,謝謝! 回上一頁. 將以下這篇報告寄給朋友. 主題. Sanofi、Regeneron最新的濕疹藥物Dupixent研究結果正面.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#25赛诺菲用于治疗特应性皮炎的单抗药物Dupixent(dupilumab)获 ...
2017年3月28日,美国FDA批准赛诺菲公司研发的单抗药物Dupixent (dupilumab)上市,用于治疗特应性皮炎(atopic dermatitis)。Dupilumab是IL-4/IL-13单 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#26赛诺菲携全球首个湿疹靶向生物制剂亮相进博会 - 新京报
新京报讯(记者张秀兰)第二届进博会期间,赛诺菲携特应性皮炎靶向生物制剂Dupixent亮相。该药是全球首个也是目前唯一获得美国食药监局(FDA)及欧盟 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#27再生元(REGN.US)和赛诺菲(SNY.US)抗体Dupixent获FDA突破 ...
US)和赛诺菲(SNY.US)公司联合宣布,美国FDA已经授予双方联合开发的重磅IL-4/IL-13抑制剂Dupixent(dupilumab)突破性疗法认定,用于治疗12岁以上的嗜 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#28搶賽道,賽諾菲中國2020的新選擇 - 每日頭條
來源:藥明康德如侵可刪今天,美國FDA批准了Dupixent(dupilumab)注射治療中度至重度濕疹(特應性皮炎,atopic dermatitis)的成年患者。
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#29賽諾菲與再生元抗炎藥dupixent獲准用於中度至重度哮喘兒童 ...
賽諾菲 (Sanofi)與再生元(Regeneron)近日宣佈,美國食品和藥物管理局(FDA)已受理抗炎藥Dupixent(中文商品名:達必妥,通用名:度普利尤單 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#30Sanofi Succeeding with Blue-Chip Asset, Dupixent, While ...
In its year-end financial report, Sanofi said sales of Dupixent were driven by continued strong demand in atopic dermatitis (AD) in adult and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#31赛诺菲“百亿重磅”或遇围堵?本土创新蜂拥布局!
Dupixent 是赛诺菲/再生元合作开发的一款靶向IL-4R的单克隆抗体药物,自2017年3月首次获得美国FDA批准后,Dupixent就显示出了惊人的市场爆发力。在此前赛诺 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#32Sanofi's Dupixent met study endpoints in children with atopic ...
Sanofi has announced positive top-line, Phase III results for Dupixent (dupilumab) in children aged six to 11 years old with atopic ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#33輝瑞異位性皮膚炎新藥臨床三期成果積極 - 工商時報
有望挑戰賽諾菲暢銷藥Dupixent ... 美國時間12日,輝瑞(Pfizer)宣佈了其實驗性口服療法abrocitinib的臨床三期結果,結果證實其功效有望可打敗對手賽諾菲與 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#34醫療保健精選——FDA批准再生元和賽諾菲的Dupixent新配方
再生元(REGN + 2.7%)和合作夥伴賽諾菲(SNY + 1.5%)宣佈,FDA批准300毫克Dupixent(dupilumab)單劑量製劑用於治療至少12歲的特應性皮炎、哮喘或患 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#35【經濟日報】合一今停牌兩個可能 - MICROBIO GROUP
... 該領域目前全球唯一上市的AD新藥是賽諾菲(Sanofi)的Dupixent,在上市 ... 合一旗下的FB825在長達一年的人體功效驗證性實驗後,證實有與Dupixent ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#36賽諾菲正在台灣Taipei City 台北招募Sales Representative - Dupixent ...
發表於上午9:22:59。RequirementsMinimum 3 years' HP working experience in original company or 3-4 years' MC experience…在LinkedIn 查看此職缺與類似職缺。
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#37Sanofi and Regeneron's Dupixent wins EU approval to treat ...
Healthcare companies Sanofi and Regeneron said on Monday that their Dupixent product has won approval from the European Commission to treat ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#38Sanofi reports Dupixent lowers itch in prurigo nodularis ...
Sanofi has reported that Dupixent met the primary and all key secondary goals of Phase III trial in uncontrolled prurigo nodularis patients.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#39一流大廠告訴你這樣才叫好公司 - 今周刊
除了采視明,公司的研發能力強勁,目前有十二款產品進入臨床試驗階段,下一個被寄予厚望的新藥,是與賽諾菲共同開發的氣喘用藥「Dupilumab」,研究 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#40今日,賽諾菲、再生元重磅抗炎症療法在華獲批
今日,中國國家藥監局官網公布,賽諾菲(Sanofi)在中國提交的重磅抗炎新藥Dupixent(dupilumab注射液)已經正式獲批,該藥物於去年年底提交上市申請 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#41下一个超百亿药物?赛诺菲/再生元披露Dupixent治疗婴幼儿 ...
美国东北时间12月13日,赛诺菲和再生元披露了Dupixent三期试验Liberty Ad Preschool的积极数据。与目前标准治疗的外用皮质类固醇联合使用, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#42FDA 批准赛诺菲Dupixent 用于治疗哮喘 - 呼吸- 丁香园
英国路透社10月19日报道,法国赛诺菲今天表示,美国FDA批准公司旗下湿疹药物Dupixent作为一种额外的维持治疗药物用于两种哮喘患者治疗。
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#43Akeso, Inc. 康方生物科技(開曼)有限公司
AK120同靶點藥物賽諾菲(Sanofi)和再生元(Regeneron)公司共同開發的Dupilumab. (商品名Dupixent)在2019年實現了20.7億歐元的銷售額,印證了其廣闊的 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#44賽諾菲股份有限公司誠徵(中南區醫學中心) Sales Representative ...
賽諾菲 股份有限公司,(中南區醫學中心) Sales Representative - Dupixent,Job Purpose: • Achieve annual sales target for territory.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#45DUPIXENT® (dupilumab injection) now publicly reimbursed in ...
MISSISSAUGA, ON, May 25, 2021 /CNW/ - Sanofi Canada is pleased to announce that Ontario and New Brunswick have listed DUPIXENT® (dupilumab injection) on ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#46赛诺菲的Dupixent在赢得胜利后获得了25亿美元的高峰期哮喘 ...
FDA签署了Sanofi和Regeneron的Dupixent作为对嗜酸性粒细胞表型的12岁及以上哮喘患者或依赖口服皮质类固醇的哮喘患者的附加维持治疗。正如Leerink分析师 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#47Pfizer drug bests Sanofi, Regeneron's Dupixent in head-to ...
Dive Brief: An experimental inflammatory disease medicine being developed by Pfizer bested Sanofi and Regeneron's top-selling therapy Dupixent ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#48赛诺菲:积极推动多元化 - 医药经济报
赛诺菲 主要增长动力是Dupixent(dupilumab),该药在2017年3月获得美国FDA批准用于治疗成人中重度特应性皮炎(湿疹),2018年10月又新增了哮喘的适应 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#49赛诺菲Dupixent获欧盟批准,首个治疗≥12岁青少年中重度特应 ...
法国制药巨头赛诺菲(Sanofi)与合作伙伴再生元(Regeneron)近日联合宣布,欧盟委员会(EC)已批准抗炎药Dupixent(dupilumab),用于适合系统疗法的 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#50Dupixent helps put Sanofi back on growth track - PMLiVE
Gains for vaccine division Sanofi Pasteur and the company's specialty medicines division, which along with Dupixent includes Genzyme's rare ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#51新型抗炎藥!賽諾菲/再生元Dupixent治療6-11歲兒童重度特應性 ...
2020年04月07日訊/. 生物谷. BIOON/ --賽諾菲(Sanofi)與合作夥伴再生元(Regeneron)近日在2020年革新特應性皮炎(Revolutionizing Atopic Dermatitis,RAD)虛擬 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#52杜避炎注射劑300 毫克(DUPIXENT solution for injection 300mg ...
賽諾菲 股份有限公司. 含量規格劑型. 300 mg/2ml;2 毫升預充填注射針筒裝;皮下注射劑. 主管機關許可適應症. DUPIXENT 可用於治療中度至重度異位性皮膚炎且對局部處.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#53Dupixent «sanofi-aventis» - Felleskatalogen
Siste besøkte sider (deaktiveraktiver) Dupixent - pasient. Dupixent. sanofi-aventis. Virkestoff: Dupilumab. Utleveringsgruppe C. Reseptbelagt legemiddel.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#54Sanofi files Dupixent for severe asthma - PharmaTimes
US regulators have accepted for review Sanofi/Regeneron's biologic Dupixent as an add-on maintenance treatment in certain adults and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#55公司簡介
賽諾菲 (Sanofi)預計銷售量將超過110億 ... 25-50%出現結膜炎症狀:Wollenberg等人(2018), 以dupilumab治療異位性皮膚炎病患發生結膜炎-臨床特徵與治療。
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#56赛诺菲重磅特应性皮炎新药Dupixent在中国获批 - 财富号
6月19日,赛诺菲Dupilumab注射液(英文商品名:Dupixent)在中国获批上市,用于治疗中至重度特应性皮炎。Dupilumab也是我国《第二批临床急需境外 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#57Dupixent增長70%衝刺百億!CD38單抗4300萬歐元 - 富途牛牛
醫藥魔方本文源自微信公眾號“醫藥魔方”。2月5日,賽諾菲(SNY.US)公佈2020年業績,淨收入360.41億歐元,同比下滑0.2%。其中製藥業務收入256.74億 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#58系首個治療中重度特應性皮炎(AD)的靶向生物療法 - Zi 字媒體
法國製藥巨頭賽諾菲(Sanofi)與合作夥伴再生元(Regeneron)近日宣布,美國FDA已批准Dupixent(dupilumab)注射液用於外用處方葯無法充分控制病情或 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#59与再生元制药合作开发抗炎药Dupixent再获美国FDA批准_财经网
财经网产经讯赛诺菲(SNY.US)宣布,公司与再生元制药(REGN.US)合作开发的抗炎药Dupixent(dupilumab)已获美国FDA批准,用于治疗12岁及以上嗜酸性粒细胞 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#60Sanofi, Regeneron gear up for new Dupixent filing after ...
This fall's harvest is proving fruitful for Dupixent. Days after touting a clean Phase III sweep in prurigo nodularis, Sanofi and Regeneron ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#61法國賽諾菲濕疹用藥熱賣效應上季每股盈餘增9.8% | 一分鐘看世界
賽諾菲 5日公布財報,上季以固定匯率計算的每股盈餘增加9.8%, ... 獲利增幅與去年的9.2%相去不遠,歸功於旗下濕疹用藥杜避炎(Dupixent)銷售看俏。
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#62赛诺菲提交度普利尤单抗注射液新适应症上市申请 - OFweek
智通财经APP获悉,根据中国国家药品监督管理局药品审评中心(CDE)最新公示,赛诺菲(SNY.US)在中国提交了度普利尤单抗注射液(dupilumab)的新适应 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#63研发客- 赛诺菲ATS 2021的关键数据显示Dupixent®(dupilumab)显 ...
赛诺菲 ATS 2021的关键数据显示Dupixent®(dupilumab)显着降低了儿童的哮喘发作并改善了肺 ... Dupixent is the only biologic medicine to improve lung function in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#64法國賽諾菲預期新療法獲益40億美金
法國知名大藥廠賽諾菲(Sanofi) 即將在美國銷售治療嚴重特應性皮膚炎之藥劑,在月底應能得到美國食品藥品監督管理局之(FDA)核准。 命名為Dupixent之 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#65長期飽受中度至重度異位性皮膚炎困擾生物製劑療法助一把
本衛教文章由賽諾菲協助提供). 備註:. 1. Blauvelt et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#66台灣鼻科醫學會» 鼻知杜明Dupixent Launch Symposium
鼻知杜明Dupixent Launch Symposium. 發佈者: é¼»ç§'å¸è¡“è ¯èª¼æœƒ | 學術研討會 ... 報名網址:https://form.ievent.tw/dupi1127 主辦單位:賽諾菲股份有限公司 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#67赛诺菲/再生元Dupixent哮喘新适应症获批在即 - 药物在线
法国制药巨头赛诺菲(Sanofi)与合作伙伴再生元(Regeneron)近日联合宣布,欧洲药品管理局(EMA)人用医药产品委员会(CHMP)已发布积极意见, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#68FB825藥品市場潛力上看100億歐元?合一:應係指賽諾菲的 ...
FB825藥品市場潛力上看100億歐元?合一:應係指賽諾菲的Dupixent藥物銷售峰值 · 1.事實發生日:109/04/16 · 2.公司名稱:合一生技股份有限公司 · 3.與公司關係( ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#69疫情持续影响至二季度,Dupixent在华获批扩版图放量可期
该药于2017年首次在美. 国获批哮喘适应症,目前已经在全球34个国家或地区上市销售。 赛诺菲药品部门按疾病领域净收入增速(单位:亿美元). 特异性皮炎 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#70賽諾菲濕疹靶向新藥Dupixent在美獲批! - 華文網
法國巴黎時間3月28日,賽諾菲和Regeneron製藥公司宣佈,美國食品藥品監督管理局(FDA)批准了其濕疹新藥Dupixent(dupilumab)注射治療中度至重度濕疹(特 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#71法藥廠賽諾菲停糖尿病藥研發- 全球財經 - 中時新聞網
法國藥廠賽諾菲(Sanofi)9日宣布,在歷經多年努力仍無法取得具體成果的情況下,該公司將停止研發糖尿病新藥。這是新任執行長哈德森(Paul Hudson) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#72「藥神」拚了10億美元買下濕疹特效新藥專利權
賽諾菲 公司研發的單抗藥物Dupixent 去年中上市,用於治療異位性皮炎,諾華買下 MOR106 的專利權,意味在此領域中將挑戰賽諾菲和Regeneron 藥物公司。
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#73賽諾菲19年財報:Dupixent驚艷突破!BTK或革新多發性硬化症 ...
最驚艷的當屬治療特應性皮炎的Dupixent(dupilumab),上市3年就突破了20億歐元,賽諾菲更是直言對Dupixent抱有銷售峰值超過100億歐元的預期。
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#74【经济日报】合一15日暂停交易业界估重磅新药将授权
FB825涵盖两大适应症,包括异位性皮肤炎(AD)、过敏性气喘。AD方面,该领域目前全球唯一上市的AD新药是赛诺菲(Sanofi)的Dupixent,在上市的第三年,即 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#75杜避炎注射劑300 毫克DUPIXENT solution for injection 300mg
DUPIXENT 於成人病患的建議劑量為一劑起始劑量600 毫克(300 毫克注射兩劑),接著以. 300 毫克隔週(every other week) ... 藥商:賽諾菲股份有限公司.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#76赛诺菲/再生元Dupixent(dupilumab)达必妥在中国获批用于特异 ...
赛诺菲 和再生元制药的Dupixent(dupilumab)达必妥/度匹鲁单抗已获得中国国家药品监督管理局(NMPA)的批准,可用于治疗中度至重度特应性皮炎的成年人。
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#77賽諾菲Regeneron:Dupixent擊中6歲以下特應性皮炎的終點 - Moomoo
賽諾菲 DJ Regeneron:Colin Kellaher Regeneron製藥公司和賽諾菲安萬特週一表示,Dupixent擊中了6歲以下特應性皮炎的終點,這是一項關於他們阻滯性的第三階段研究.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#78赛诺菲2020Q1财报:Dupixent增长130%冲击百亿梦想
4月23日,赛诺菲发布2020Q1财报,净收入达到89.73亿欧元,同比增长6.9%,高于2019年全年4.8%的同比增幅。在疫情全球蔓延对药企业务经营普遍带来严重 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#79赛诺菲Dupixent(达必妥)获国家药监局批准 - 香港就医
近日,赛诺菲(Sanofi)与再生元(Regeneron)联合宣布,欧洲药品管理局(EMA)人用医药产品委员会(CHMP)已发布一份积极审查意见,建议批准扩大Dupixent (中文商品 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#80Dupilumab獲美國FDA核准用於12-17歲中重度異位性皮膚炎
生物製劑已經在各個疾病領域使用許久. 而Dupilumab(商品名: Dupixent/杜必炎, Sanofi & Regeneron藥廠)是異位性皮膚炎的第一支生物製劑。
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#81異位性皮膚炎標靶藥物「杜避炎」:療效、副作用、使用方式
「我沒辦法時常回診,若是兩個禮拜打一次又有效的話,我可以配合。」 ▽異位性皮膚炎的標靶藥物:杜避炎(Dupixent或Dupilumab). 杜避炎,異位性 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#82新型抗炎药!赛诺菲/再生元Dupixent(达必妥
2020年09月09日讯/BIOON/ --赛诺菲(Sanofi)与再生元(Regeneron)近日在2020年欧洲呼吸学会(ERS)国际上公布了抗炎药Dupixent(中文商品名:达必 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#83Lilly's atopic dermatitis med scores another late-stage win in ...
Watch out, Sanofi and Regeneron. Eli Lilly's Dupixent rival has posted another round of data showing improvement in atopic dermatitis when ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#84RBD Alliance Manager, Sanofi Genzyme Field Operations ...
Program Manager - RBD Alliance Manager, Sanofi Genzyme Field Operations Manager - Dupixent Area Business Manager (Dupixent) at Sanofi in Cambridge.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#85Pharma giant Sanofi renews commitment to China through CIIE
Dupixent, which made its debut at the first CIIE, became the first and only biological medicine approved for the treatment of atopic dermatitis ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#86Sanofi/Regeneron's asthma blockbuster Dupixent has new ...
As a result, the drug will go up against the Sanofi SA and Regeneron Inc.'s blockbuster injection, Dupixent (dupilumab), which inhibits IL-4/IL- ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#87Top Stock Reports for NVIDIA, Philip Morris & Sanofi
The Zacks analyst believes that Dupixent has become the key top-line driver for Sanofi due to its regular label expansion.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#88Sanofi-Aventis S.A. - The New York Times
News about Sanofi-Aventis S.A., including commentary and archival articles published in The New York Times.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#89Conserver les turbo calls Sanofi - Investir - Les Echos
Le groupe pharmaceutique devrait enregistrer en 2022 une progression toujours dynamique tirée notamment par la performance de Dupixent.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#90SANOFI Cours Action SAN, Cotation Bourse Euronext Paris
Le cours de l'action SANOFI SAN en temps réel sur Boursorama : historique de la cotation sur Euronext Paris, graphique, actualités, consensus des analystes ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#91Black Children Not Prioritized In Asthma Drug Study, Despite...
Sanofi and Regeneron Pharmaceuticals recently published the results of the clinical trial for Dupixent, or Dupilumab, a treatment for ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#92Management of Patients with AD on Dupilumab - Dermatology ...
Dupilumab (Dupixent; Sanofi and Regeneron) is approved to treat moderate to severe atopic dermatitis (AD) in patients 6 years and older.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#93The Zacks Analyst Blog Highlights: NVIDIA, Philip Morris ...
The Zacks analyst believes that Dupixent has become the key top-line driver for Sanofi due to its regular label expansion.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#94Sanofi rachète la biotech américaine Amunix pour au moins ...
Selon les termes de l'accord, Sanofi fera l'acquisition d'Amunix pour un paiement initial d'un milliard de dollars, assorti de 225 millions de ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#95Top Stock Reports for NVIDIA, Philip Morris & Sanofi - Zacks
The Zacks analyst believes that Dupixent has become the key top-line driver for Sanofi due to its regular label expansion.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#96Sanofi, GSK report positive preliminary booster data for ...
Sanofi (SNY) and GlaxoSmithKline (GSK) announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#97Vaccin: Sanofi publiera ses résultats définitifs premier trimestre
Le laboratoire français Sanofi prévoit désormais de publier les résultats finaux de son essai clinique sur son vaccin contre le Covid-19 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?>
dupixent賽諾菲 在 コバにゃんチャンネル Youtube 的最佳解答
dupixent賽諾菲 在 大象中醫 Youtube 的精選貼文
dupixent賽諾菲 在 大象中醫 Youtube 的精選貼文